title: [Administration of Immune Checkpoint Inhibitor for Cancer except for Melanoma and Lung Cancer].
abstract: We treated 19 cancer patients with cancer types other than melanoma and lung cancer with immune checkpoint inhibitors, between June 2015 and April 2016. We administered nivolumab at 2-3mg/kg bw every 2-3 weeks. One patient received 14 doses, 5 received 6 doses, 3 received 5 doses, 3 received 4 doses, and 3 received 3 doses. Three remarkably effective responses were seen in cases of pancreatic cancer, esophageal cancer, and brain malignant lymphoma. In every effective case, dendritic cell therapy was administered prior to nivolumab.
authors.affiliation: Osaka Cancer Immuno-Chemotherapy Center.
authors.forename: Tsutomu
authors.initials: T
authors.lastname: Takeda
authors.forename: Nobuaki
authors.initials: N
authors.lastname: Hattori
authors.forename: Takashi
authors.initials: T
authors.lastname: Takeda
authors.forename: Takehiro
authors.initials: T
authors.lastname: Noda
authors.forename: Hiroko
authors.initials: H
authors.lastname: Takeda
mesh_terms: D000368:Aged; D000911:Antibodies, Monoclonal / Q000008:administration & dosage / Q000627:therapeutic use*; D000970:Antineoplastic Agents / Q000008:administration & dosage / Q000627:therapeutic use*; D014408:Biomarkers, Tumor / Q000097:blood; D005260:Female; D006801:Humans; D008875:Middle Aged; D009362:Neoplasm Metastasis; D009369:Neoplasms / Q000737:chemistry / Q000188:drug therapy* / Q000276:immunology* / Q000473:pathology; D000077594:Nivolumab; D016896:Treatment Outcome
chemical_list: D000911:Antibodies, Monoclonal; D000970:Antineoplastic Agents; D014408:Biomarkers, Tumor; D000077594:Nivolumab